

# India's pharma sector gets a relook in Boston

Release of Special Report by PWC on the Pharma Landscape

Networking session in progress



The annual US-India BioPharma and Healthcare Summit, organized by the USA-India Chamber of Commerce (USAIC) in Boston in early June saw yet again a galaxy of healthcare leaders from both India and USA taking forward the momentum for collaborations in the field

built over the years.

Curated by USAIC President, Mr Karun Rishi, and anchored competently by Dr Raju Kucherlapati, Professor of Genetics, Harvard Medical School, the day-long event took a realistic look at the state of the healthcare industry in India.

The galaxy of pharma leaders from top US companies grudgingly admitted despite many difficult areas, India remains a huge emerging market for pharmaceutical products. They urged the nearly 200 participants to build a capability-driven strategy to emerge winners in this promising marketplace.

Participating in a fireside chat, moderated by Dr William Chin of PhRMA, eminent Japanese leader, Dr Tachi Yamada of Takeda confessed: "I prefer India over China due to the felicity with English and also the tremendous expertise offered by the returning Indian diaspora." He referred to a competitive pharma project handled by Takeda's internal team as well as that by Advinus Therapeutics of India. On every count of quality, time